1st Quarter - Report
THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS
Client
Income
$40,000
Expenses
—
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Budget/Appropriations BUD
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations, provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Defense DEF
NDAA - provisions related to biological and chemical defense.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Disaster Planning/Emergencies DIS
Monitored issues related to the material threat list.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DONALD KENT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.